# Detection and quantification of human immunodeficiency virus-1 (HIV-1) total nucleic acids in wastewater settled solids from two California communities

3

Marlene K. Wolfe\*<sup>1</sup>, Bridgette Shelden<sup>2</sup>, Dorothea Duong<sup>2</sup>, Meri R.J. Varkila<sup>3</sup>, Bradley J. White<sup>2</sup>,
 Julie Parsonnet<sup>3,4</sup>, Alexandria B. Boehm<sup>5</sup>

- 6
- 7 1. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory
- 8 University, 1518 Clifton Rd, Atlanta, GA, USA, 30322
- 9 2. Verily Life Sciences LLC, South San Francisco, CA, USA
- 10 3. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford
- 11 University, 300 Pasteur Drive, Stanford, California, 94305
- 12 4. Department of Epidemiology and Population Health, Stanford University, 300 Pasteur Drive,
- 13 Stanford, California, 94305
- 14 5. Department of Civil and Environmental Engineering, Stanford University, 473 Via Ortega,
- 15 Stanford, California, 94305
- 16

18

17 \* Author to whom correspondence should be addresses: marlene.wolfe@emory.edu

### 19 Abstract

- 20 Wastewater surveillance for infectious agents has proved useful in identifying circulation of
- 21 viruses within populations. We investigated the presence and concentration of human
- 22 immunodeficiency virus (HIV)-1 total nucleic acids (including both viral RNA and proviral DNA)
- 23 in wastewater solids. We retrospectively measured HIV-1 nucleic-acids in two samples per
- 24 week for 26 months at two wastewater treatment plants serving populations with different
- 25 prevalences of HIV infections in San Francisco and Santa Clara County, California, USA. We
- 26 detected HIV nucleic-acids in a majority of samples with concentrations ranging from non-detect
- to  $3.9 \times 10^5$  cp/g (N=459 samples total). Concentrations of HIV-1 were significantly higher in
- samples from the wastewater treatment plant serving a population with a higher prevalence of
- people living with HIV than in the plant serving a population with lower prevalence. The HIV-1
   nucleic-acids amplified were primarily DNA and thus represented proviral DNA shedding into
- 31 wastewater. Additionally, we found that HIV-1 nucleic-acid concentrations in wastewater solids
- 32 were orders of magnitude higher than those in liquid wastewater indicating that the HIV-1 target
- 33 preferentially sorbs to solids. Whether concentrations of HIV-1 in wastewater solids can be used
- 34 to identify numbers of incident cases remains unknown. Additional work on HIV-1 shedding from
- 35 individuals with viremia and people living with HIV is needed to translate wastewater
- 36 measurements to quantitative information on infections.
- 37

## 38 Introduction

- 39 Despite advances in prevention and treatment and a decrease in new human immunodeficiency
- 40 virus (HIV) infections, more than 600,000 people die from acquired immunodeficiency syndrome
- 41 (AIDS) annually<sup>1</sup>. The Ending the HIV Epidemic in the United States (EHE) initiative has set an
- 42 ambitious goal of reducing the number of new HIV infections in the US by 90% between 2019
- 43 and 2030. Progress, however, has been below target and disproportionately slow in some
- 44 demographic groups and geographic regions. At the end of 2021, there were an estimated 1.2

45 million people living with HIV (PLWH) in the US and 36,136 people who were newly

46 diagnosed<sup>2,3</sup> [ref].

47

48 Minoritized people are disproportionately affected by the HIV epidemic in the US; 40% of people 49 receiving a new diagnosis in the US in 2021 were Black<sup>2</sup>. Although it has been estimated that 50 87% of those living with HIV in the US are aware of their status, during the COVID-19 51 pandemic, HIV testing and new diagnoses decreased. Consequently, a greater proportion of 52 PLWH may be unaware of their status and the CDC has identified specific geographic regions where underdiagnosis may be particularly problematic <sup>4–7</sup>. Systemic barriers to care, 53 54 exacerbated by the pandemic, may continue to slow progress towards EHE goals. Ongoing 55 assessment of the prevalence of HIV infection in communities, especially those underserved by 56 healthcare and testing centers, is critical to provide resources that ensure consistent testing 57 and subsequent treatment.

58

59 Wastewater monitoring has not been previously applied to HIV but could help identify trends in

60 infection prevalence and identify pockets of underdiagnosed infection. Wastewater, a naturally

61 composited biological sample that includes bodily secretions, has been used to monitor a wide

62 range of infectious diseases including respiratory viruses, enteric viruses, dengue (an arbovirus)

63 and mpox (a poxvirus).<sup>8–14</sup> Wastewater monitoring was effectively used to support mpox

response at the start of the outbreak in the United States during summer 2022<sup>10</sup>; providing

- 65 information to respond to an outbreak that was syndemic with HIV.
- 66

67 Although the use of wastewater monitoring for HIV has not been explored, evidence from early 68 in the HIV pandemic suggests that viral RNA and DNA can be detected in wastewater. Several studies from the early 1990's demonstrated the detection of HIV nucleic acids and intact virus in 69 natural wastewaters<sup>15,16</sup> and detectability of the virus seeded in wastewater<sup>17,18</sup>. These studies 70 were focused on occupational hazard, rather than monitoring. Some data indicate that HIV 71 72 nucleic acids are shed in urine and feces of people living with HIV (PLWH), even those who are virally suppressed <sup>19–21</sup>. Contributions to wastewater therefore may be expected from people 73 74 living with HIV. This suggests that detection and quantification for monitoring of HIV infections at 75 the community level is a realistic possibility. 76

The goal of this study is to apply testing for HIV RNA and DNA to wastewater samples from two adjacent counties to determine whether consistent detection and quantification of HIV nucleic acids in wastewater is feasible, and explore the relationship of these measurements to the

80 overall estimated rates of people living with HIV in the associated communities.

81

#### 82 <u>Methods</u>

83 Study design and sample collection. We conducted a longitudinal retrospective analysis of

84 HIV nucleic acids in wastewater solids from two wastewater treatment plants (WWTPs) in the

85 San Francisco Bay Area, California (CA), USA. Fifty milliliters (50 ml) samples of wastewater

solids were collected from primary clarifiers daily using sterile methods, and biobanked with

87 consent of the participating WWTPs as part of a routine wastewater monitoring program that

88 began in November 2020. Two samples per week covering a period of 26 months were selected

for this study. They were collected between 2 Feb 2021 and 14 April 2023 (459 samples total).

90 The two WWTPs included in the retrospective analysis serve ~75% (1,500,000 people) of Santa

91 Clara County, (SJ) and ~25% (250,000 people) of San Francisco County (OSP), CA. Further

92 WWTP descriptions are elsewhere<sup>22</sup>. These sites were selected and tested as part of a

93 retrospective study measuring nucleic acids from a panel of viruses that are candidates for

94 wastewater monitoring; HIV-1 was one of the targets selected for inclusion in this study.

95 Samples were stored at 4°C, transported to the lab, and processed within six hours. Solids were

96 then dewatered using centrifugation<sup>23</sup> and then frozen at -80°C for 4 - 60 weeks.

97

98 We collected additional samples over a consecutive 9 days to compare concentrations of HIV-1

99 between liquid wastewater and wastewater solids, and to compare measurements made with 100 and without a reverse-transcription step during the analytic analysis. Additional samples were

101 collected from two sites, OSP and a second site in San Francisco County (SEP) that serves

102 ~75% of the county (650,000 people). For these two sites, 24-hour composite samples of raw

103 wastewater influent (liquid) and a grab sample of solids from the primary clarifiers were

104 collected on the same day for 8 days in early July 2023, and one additional solids samples was

105 collected from SEP (Table S1, samples hereafter labeled 1-8 for OSP and SEP liquid, and 1-8

and 1-9 for OSP and SEP solids, respectively). All the solids samples (n=17) were tested for

107 HIV-1 target using both RT-PCR and PCR to gain insight into the proportion of HIV-1 RNA and

108 DNA in the samples, respectively (Table S1). Samples were stored at 4°C for the duration of

the 9 day study and then underwent pre-analytical and analytical processing without any

additional storage. Solids were dewatered immediately using centrifugation<sup>23</sup> and subsequently

111 processed for nucleic-acid extraction without storage.

112

113 Solids pre-analytical methods. Frozen, dewatered solids were thawed overnight at 4°C. 114 Solids were resuspended in DNA/RNA Shield (Zymo Research, Irvine, CA) at a concentration of 115 approximately 0.75 mg (wet weight)/ml. This concentration was chosen as it was shown to reduce inhibition in RT-PCR applications with extracted nucleic acids<sup>24</sup>. A separate aliguot of 116 117 dewatered solids was dried in an oven to determine its dry weight, and the calculated percent 118 solids was used to express concentrations of nucleic acid targets in units of per gram dry 119 weight. These pre-analytical methods are described thoroughly in a publicly accessible 120 protocol<sup>25</sup>. Nucleic-acids were extracted from 10 replicate aliquots of dewatered settled solids 121 suspended in the DNA/RNA Shield using the Chemagic Viral DNA/RNA 300 kit H96 for the 122 Perkin Elmer Chemagic 360 (Perkin Elmer, Waltham, MA) followed by PCR inhibitor removal with the Zymo OneStep-96 PCR Inhibitor Removal kit (Zymo Research, Irvine, CA). 300 µl of 123 124 the suspension entered into the nucleic-acid extraction process and 50 µl of nucleic-acids are 125 retrieved after the inhibitor removal kit. Negative extraction controls consisted of BCoV-vaccine 126 spiked DNA/RNA Shield. Nucleic acid extracts for the biobanked wastewater samples used in 127 the retrospective study were stored at  $-80^{\circ}$ C for different amounts of time (8-273 days, median = 128 266 days) and subjected to one freeze thaw prior to analysis. Nucleic-acids from the solids 129 samples used for the liquid/solid comparison and with/without reverse-transcription were not 130 stored prior to analysis.

132 Liquids pre-analytical methods. Viral particles were concentrated from wastewater using an

- 133 affinity-based capture method with magnetic hydrogel Nanotrap Particles (Ceres Nanosciences,
- 134 Manassas, VA). Samples were spiked with BCoV before concentration, and used to assess
- nucleic acid recovery. For each sample, 10 replicate aliquots of 10 mL of liquid wastewater were
- 136 concentrated using the Nanotrap Particles and Enhancement Reagent 1 on a KingFisher Flex
- 137 system. Nucleic acids were then extracted from each replicate with the MagMAX Viral/Pathogen
- 138 Nucleic Acid Isolation Kit (Applied Biosystems, Waltham, MA) using the KingFisher Flex system.
- 139 Resulting nucleic acids were then processed through a Zymo OneStep-96 PCR Inhibitor
- 140 Removal kit (Zymo Research, Irvine, CA). Each 10 ml sample resulted in 50 µl total nucleic acid
- 141 extract. Note that suspended solids were not removed prior to initiating these methods, and the
- 142 nucleic-acids were not stored prior to analysis.
- 143

#### 144 HIV (Reverse-transcription)- polymerase chain reaction assay choice

- 145 We selected previously published HIV genome-specific primers and probes targeting the long
- terminal repeat (LTR) region of the HIV-1 genome for use in this study; the assay chosen does
- 147 not target HIV-2<sup>26</sup>. We used the 496F/546P/622R primers and probe as recommended by
- 148 Kibirige et al.<sup>27</sup> The assay uses primers and probes originally described in Brussels et al.<sup>28</sup> and
- 149 Friedrich et al. <sup>29</sup> (Table 1).
- 150
- 151 To confirm HIV-1 assay specificity, the assay was challenged with non-target viruses including 152 those in two panels purchased from Zeptomatrix (Buffalo, NY), NATRVP2.1-BIO and NATEVP-
- 153 C, along with HIV-2 (ATCC PTA-9773). The NATRVP2.1-BIO panel includes chemically
- 154 inactivated intact influenza viruses, parainfluenza viruses, adenovirus, rhinovirus,
- 155 metapneumovirus, and coronaviruses. The NATEVP-C panel includes chemically inactivated
- 156 intact coxsackieviruses, echovirus, and parechovirus. To confirm HIV-1 assay sensitivity,
- 157 synthetic HIV-1 RNA (ATCC VR-3351SD) was used as a positive control for HIV-1. American
- 158 Type Culture Collection (ATCC) controls are synthetic RNA. Nucleic-acids (NA) were extracted
- 159 from intact viruses using the Chemagic Viral DNA/RNA 300 kit H96 (PerkinElmer, Waltham,160 MA).
- 160
- 161 162
- 163 **Digital-droplet RT-PCR methods.** For sensitivity and specificity testing of the HIV-1 assay, 164 nucleic-acids were used undiluted as template in digital RT-PCR reactions in a single well. No 165 template negative RT-PCR controls using molecular grade water as template were included in 166 each plate. The assay was run in simplex with only primers and probe in Table 1.
- 167
- 168 Wastewater samples were tested for HIV-1 nucleic-acids as well as pepper mild mottle virus 169 (PMMoV) using droplet digital RT-PCR. PMMoV is a pepper virus that is highly abundant in
- 170 wastewater across the world and used in this study as an endogenous recovery control, as well
- 171 as a measure of fecal strength of the wastewater<sup>30</sup>. We did not utilize an exogenous extraction
- 172 control (such as a spiked virus like bovine coronavirus) due to the difficulty in interpreting
- 173 recovery with an exogenous target<sup>31</sup>; however this method has consistently provided high
- 174 recoveries approaching 100% of spiked BCoV in our laboratories<sup>22</sup>.
- 175

176 Each of the 10 replicate nucleic-acid wastewater extracts was used as template undiluted in its 177 own well (10 wells per sample) to measure HIV-1 and PMMoV. The HIV-1 assay was run in multiplex using a probe mixing approach with seven other assays targeting genomes of 178 179 rotavirus, influenza A subtype markers H1 and N1, SARS-CoV-2, human norovirus GII, human 180 adenovirus group F, and West Nile virus (results not reported herein, but provided elsewhere<sup>32,33</sup>). Multiplexing method testing showed that presence of seven other nucleic-acid 181 182 targets in the multiplex reaction did not affect quantification of the HIV-1 target (Figure S1). 183 Nucleic-acids were diluted 1:100 and used as template to measure PMMoV using methods outlined in detail elsewhere<sup>22</sup> and thoroughly in a protocols.io protocol<sup>34</sup> (Table S2 provides 184 primers and probe). Extraction negative (DNA/RNA shield, 3 wells) controls, and PCR negative 185 186 (molecular grade water, 3 wells) and positive controls (synthetic RNA, 1 well) were run on each 187 96 well plate. Any failure of these controls resulted in re-processing of the samples, and any 188 samples with anomalously low PMMoV would also be rerun or discarded from analysis. 189 190 ddRT-PCR was performed on 20 µl samples from a 22 µl reaction volume, prepared using 5.5 µl 191 template, mixed with 5.5 µl of One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad 192 1863021), 2.2 µl of 200 U/µl Reverse Transcriptase, 1.1 µl of 300 mM dithiothreitol (DTT) and 193 primers and probes mixtures at a final concentration of 900 nM and 250 nM respectively. Primer 194 and probes for assays were purchased from Integrated DNA Technologies (IDT, San Diego, 195 CA) (Table 1 and S2). 196 197 HIV-1 nucleic-acids were quantified in the 17 solids samples collected at OSP and SEP in July 198 2023 (Table S1) using both RT-PCR and PCR without the RT step. RT-PCR was run as 199 described above for the biobanked wastewater samples. PCR was run using the same method 200 as for RT-PCR but the RT enzyme and DTT were omitted from the mastermix. As a control, the

concentration of the N gene of SARS-CoV-2 was examined from the multiplex assay as the N
 gene is expected to only be detected when an RT step is included as it resides in wastewater as
 genomic RNA. We confirmed that the N gene was not detected without the RT step indicating
 lack of RT activity in that mastermix.

205

206 Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad, Hercules, 207 CA). PCR was performed using Mastercycler Pro (Eppendforf, Enfield, CT) with the following 208 cycling conditions: reverse transcription at 50 °C for 60 min, enzyme activation at 95 °C for 209 5 min, 40 cycles of denaturation at 95 °C for 30 s and annealing and extension at 59 °C (for HIV-210 1) or 56 °C (for PMMoV) for 30 s, enzyme deactivation at 98 °C for 10 min then an indefinite hold 211 at 4 °C. The ramp rate for temperature changes were set to 2 °C/second and the final hold at 212 4 °C was performed for a minimum of 30 min to allow the droplets to stabilize. Droplets were 213 analyzed using the QX200 or the QX600 Droplet Reader (Bio-Rad). A well had to have over 214 10,000 droplets for inclusion in the analysis. All liquid transfers were performed using the Agilent 215 Bravo (Agilent Technologies, Santa Clara, CA). 216

Thresholding was done using QuantaSoft<sup>™</sup> Analysis Pro Software (Bio-Rad, version 1.0.596)
for data generated using the QX200 and QX Manager Software (Bio-Rad, version 2.0) for data

generated using the QX600. In order for a sample to be recorded as positive, it had to have atleast 3 positive droplets. Replicate wells were merged for analysis of each sample.

221

222 Dimensional analysis was used to convert concentrations of nucleic-acid targets from copies per

reaction to copies per dry weight of solids (cp/g) or copies per milliliter (cp/ml) of influent.

224 Measurement errors are reported as standard deviations. The lowest detectable concentrations

were ~500-1000 cp/g for solids and 1 cp/ml for liquids, respectively, and is equivalent to the

- concentration giving rise to three positive droplets across 10 merged well. The range provided for solids reflects differences in the dry weight of different solids samples. Wastewater data for
- for solids reflects differences in the dry weight of different solids samples. Wastewater data for the retrospective study are publicly available through the Stanford Digital Repository
- 229 (https://doi.org/10.25740/yz257qj0009).
- 230

#### 231 Statistics

A Wilcoxon rank sum test was used to determine if there were significant differences in the concentrations of nucleic acids between the two utilities with the alternative hypothesis that concentrations were higher at OSP than SJ. A Wilcoxon signed rank test was used to determine whether there were significant differences in the concentration estimated between matched samples tested with and without a reverse transcription step. A Wilcoxon signed rank test was

also used to determine whether there were significant differences in the concentration estimated

238 on a per mass basis (cp/g and cp/mL) between matched liquid and solids samples.

239

### 240 Clinical data

241 Estimated annual numbers of incident cases of HIV were obtained at the county level from

publicly available county health department surveillance summaries for 2021 and 2022<sup>5,35–37</sup>.

243 Estimates of PLWH and the proportions with viral suppression were also obtained from these

reports. Data for 2023 was not available at the time of writing; further details of health

245 department reporting and definitions are available in the SI. Rates of PLWH per county were

calculated based on yearly population denominators obtained from the State of California,

247 Department of Finance, Demographic Research Unit<sup>38</sup>.

248

#### 249

#### 250 <u>Results</u>

251

252 **Quality control.** Positive and negative extraction and PCR controls were positive and negative, 253 respectively indicating assays performed and no evidence of contamination. The PMMoV 254 endogenous control, as expected, was detected at relatively high concentrations in wastewater 255 (median (range) log<sub>10</sub>-transformed PMMoV = 9.1 (8.5-10.2) and 8.7 (8.1-9.5) log<sub>10</sub> copies/g at 256 SJ and OSP, respectively). Given that the lowest measurements at the two sites were within an 257 order of magnitude of the medians, we concluded that there was no gross extraction failure. 258 Further details of the methods and controls per the Environmental Microbiology Minimal 259 Information (EMMI) guidelines can be found in the supporting materials (Figure S2). 260

We compared PMMoV measured using the biobanked and stored samples to PMMoV measured in the same samples when processed immediately for a routine wastewater

surveillance project As described in Boehm et al.<sup>39</sup>, median (interquartile range) ratio of PMMoV
RNA measurements made in this study to those made using fresh samples was 0.9 (0.6-1.2) at
SJ and 1.0 (0.7-1.4) at OSP suggesting limited degradation of the PMMoV RNA target in the
stored and freeze thawed samples. It should be noted that there could have still been
degradation of HIV-1 nucleic-acids in these biobanked samples, especially since the N gene
from SARS-CoV-2 has shown some losses under these storage conditions<sup>39</sup>; however, sample
storage is essential for retrospective work.

270

Analysis of HIV-1 in wastewater. HIV-1 nucleic-acids (NA) were detected consistently throughout the retrospective study period in both OSP and SJ wastewater (Figure 1). HIV-1 NA were detected in 94% (215/230) of samples from OSP and 23% (53/229) of samples from SJ. Measured HIV-1 NA concentrations were significantly higher at OSP compared to SJ (Wilcoxon rank sum test,  $p<10^{-16}$ , Figure 1). At OSP, concentrations ranged from non-detect to  $3.9x10^5$ cp/g with a median 7.3x10<sup>3</sup> cp/g. At SJ, concentrations ranged from non-detect to  $1.1x10^5$  cp/g with a median of non-detect.

278

279 Measured HIV-1 NA concentrations were significantly different in solids compared to liquids 280 (Wilcoxon signed rank test,  $p < 10^{-3}$ ). Concentrations in solids were enriched by several orders 281 of magnitude compared to liquids on a per mass basis with a median concentration of 1 cp/mL 282 in liquids and 6142 cp/g in solids across all samples included in the comparison (Fig 2). Liquid 283 samples also had a higher rate of nondetection for HIV-1; HIV-1 NA were not detected in 4/16 284 liquids samples and 2/16 solids samples. One sample had no HIV-1 NA detected by either 285 method.

286

When analyzed with and without a reverse transcription step, HIV-1 NA in wastewater were significantly different (Wilcoxon signed rank test, p = 0.03) but the magnitude of the difference between the two was small (Fig 3; with RT median = 5773 cp/g and mean = 8734 cp/g, without RT median = 8012 cp/g and mean = 10296 cp/g).

291

Clinical Data. The number of new diagnoses of HIV from San Francisco was similar to the
 number of new diagnoses in Santa Clara County for both 2021 and 2022 (Table 2), however as
 the population of Santa Clara County is much larger, the rate of new diagnoses per 100,000
 residents was higher in SF than in SCC. The number and rate of PLWH was also higher in San
 Francisco County compared to Santa Clara County. The two counties have similar rates of viral
 suppression, estimated at 72-73% for San Francisco and 70.2-68.1% for Santa Clara County
 from 2021 - 2022.

299

These county level HIV prevalence estimates serve as imperfect proxies for the population living in the OSP and SJ sewersheds. OSP WWTP serves 25% of the population of San Francisco county, and annual reports show that the geographic area served by the plant has lower rates of PLWH than the county as a whole<sup>37,40</sup>. Neighborhoods within the OSP service area are described as having a rate of 317-999/100,000 PLWH in 2021, and 310-799/100,000 PLWH in 2022. SJ WWTP serves 75% of the population of Santa Clara County.

- 307 Comparison of clinical and wastewater data. Overall, the rate of detection and
- 308 concentrations of HIV-1 nucleic acids were higher in San Francisco County than in Santa Clara
- 309 County and the rates of new HIV diagnoses and rates of PLWH were also higher in San
- 310 Francisco County. No statistics are applied to this comparison as clinical data is available at an
- 311 annual scale and N = 4, limiting appropriate hypothesis testing.
- 312

#### 313 Discussion

- 314 This study demonstrates a first proof of concept that HIV-1 nucleic-acids can be reliably
- 315 detected and quantified in wastewater, and rates of detection and concentration are aligned with
- 316 known information about the overall prevalence of PLWH in the associated communities. HIV-1
- 317 nucleic acids were consistently detected in wastewater from WWTPs in the San Francisco Bay
- 318 Area, California (CA), USA, with differences in wastewater rates of detection concentrations that
- 319 mirrored clinical surveillance data between counties. Both the rate of detection and
- 320 concentrations of HIV-1 nucleic acids were higher in San Francisco County than in Santa Clara
- 321 County, consistent with the higher rate of both PLWH and new HIV diagnoses in San Francisco.
- 322 Although the sewershed area served by the San Francisco County WWTP covers a part of the
- 323 city that has relatively lower prevalence of residents with PLWH, even these areas have
- 324 reported prevalence that is approximately double or more the prevalence in Santa Clara County.
- 325
- 326 HIV-1 nucleic acids were detected from both the liquid and solid portion of wastewater from two 327 sites in San Francisco County. The concentrations in solids were several orders of magnitude
- 328 higher on a per mass basis than those in liquid, and the rate of non-detection was slightly higher
- 329 in liquid samples. This suggests that HIV-1 nucleic acids can be successfully quantified in
- 330 wastewater utilizing either the solid or the liquid matrix, but the use of solids may improve the
- 331 sensitivity of the measurements. Future work utilizing liquids and solids across a wider range of
- 332 anticipated concentration of HIV-1 NA would help determine the performance of methods
- 333 utilizing each matrix at different levels.
- 334
- 335 The field of wastewater monitoring for infectious disease has grown rapidly in recent years and 336 has not only become a part of many public health department's approach to infectious disease 337 surveillance, it has been successfully used to monitor diseases like mpox that interact with HIV. 338 Wastewater monitoring has not, however, been previously used to support HIV monitoring. This
- 339 is likely because HIV has a number of important differences from other viruses commonly
- 340 monitored using wastewater such as respiratory and enteric viruses, particularly when
- 341 considering the possibility of long term shedding and how this relates to individuals with different disease outcomes<sup>19,20</sup>.
- 342
- 343
- 344 There are limited quantitative data on the concentration of HIV-1 nucleic-acids in excretions.
- 345 While individuals with active infections may shed viral RNA, PLWH who are virally suppressed
- may still excrete HIV-1 DNA<sup>19</sup>. In this study, we quantified total HIV-1 nucleic-acids which 346
- 347 include both RNA and DNA; the methods we used cannot distinguish between the two. The
- 348 overall similarity in concentrations of HIV nucleic-acids with and without reverse transcription in
- 349 a small subset of samples suggests that the majority of the nucleic-acids detected in wastewater
- 350 are DNA. Further work will need to be done to better understand shedding dynamics of HIV-1

nucleic-acids in PLWH and those with viremia to provide a foundation to further interpret theseresults.

353

354 This work presents a first proof of concept; in order to make HIV monitoring in wastewater a tool 355 that is useful for public health response to the HIV epidemic more work is necessary to 356 understand the relationship between these measurements and PLWH and even more 357 importantly the people living with undiagnosed or unmanaged HIV in the community. Multiple 358 assays in the future might be used to distinguish active HIV replication from the proviral 359 reservoir, both of which may be represented by nucleic acids in wastewater, an increase in 360 cases that are untreated vs effectively treated may be detectable. Targets in wastewater that 361 identify HIV resistance may help inform initial antiretroviral therapy (ART) choices (e.g., is the 362 virus mutating, is pre-exposure prophylaxis (PrEP) contributing to resistance, etc.) without 363 identifying or linking individuals. 364 365 Despite CDC recommendations for routine HIV screening in healthcare settings since 2006<sup>41</sup>.

366 HIV testing rates during ambulatory care visits have remained low<sup>7,42</sup>. With barriers to 367 implementation ranging from provider perceptions of low HIV risk to institutional concerns surrounding allocation of limited resources<sup>7,42</sup>, recent initiatives, such as the EHE, propose 368 refocused efforts to target areas with the highest burden of HIV <sup>43,44</sup>. With more information from 369 studies on HIV NA shedding and a closer comparison of HIV infections and wastewater data to 370 371 guide interpretation of presence and concentrations of HIV NA targets in wastewater and the 372 relationship to infection and disease outcomes, data on HIV from wastewater may be useful 373 both at a facility and community level for monitoring trends to help inform screening efforts. 374 Tools like this would provide opportunities to compare the burden of HIV across geographic 375 areas, to provide information on the scope of the HIV burden in institutions like hospitals and 376 correctional facilities, and possibly to determine patterns in resistance. This may be used to 377 determine times and places when increased screening at sites may be useful, feeding into 378 existing frameworks that identify priority areas for intervention.

379

Acknowledgements. We acknowledge Gregory Ostolaza Bravo for contributions to wastewater
 sample analysis.

- 382
- 383
- 384

**Table 1.** Primer and hydrolysis probes targeting the long terminal report (LTR) region of HIV-1.

386 The amplicon size is 127 basepairs (bp). The HIV-1 probe contained Cyanine-5 (Cy5)

387 fluorescent molecule, ZEN, a proprietary internal quencher from Integrated DNA Technologies

388 (Coralville, IA, USA); and IBFQ, Iowa Black FQ.

389

	Sequence
Forward	GGCTAACTAGGGAACCCACTG
Reverse	TCCACACTGACTAAAAGGGTCTGA
Probe	CACTCAAGGCAAGCTTTATTGAGGC

390

391 Table 2. Numbers and rates of PLWH, %PLWH who were virally suppressed, and new HIV

diagnoses in San Francisco and Santa Clara Counties in 2021 and 2022.

393

	San Francisco County		Santa Clara County	
	2021	2022	2021	2022
Total PLWH, N	11830	11798	3618	3770
PLWH per	1405.5	1399.4	190.4	198.1
100,000				
population*				
New diagnoses,	166	157	133	165
Ν				
New diagnoses	19.7	18.6	7.0	8.7
per 100 000				
population*				
Viral	72%	73%	70.2%	68.1%
suppression, %				



<sup>395</sup> 

Fig 1. Wastewater concentrations of HIV nucleic-acids. Left: Concentration of HIV nucleic-acids in wastewater solids from OSP (A) and SJ (B) expressed in terms of copies of the target per gram dry weight of solids found in wastewater. Open circles show where HIV nucleic-acids were not detected, and the errors on each point represent standard deviations (68% confidence intervals) from the droplet digital RT-PCR measurement and include Poisson error as well as variation among replicate wells. The black line represents the 5-sample smoothed and trimmed average. Right: Distribution of the concentration of HIV nucleic-acids in wastewater solids from OSP and SJ (C), in terms of copies of the target per gram dry weight of solids found in wastewater. Open circles show where HIV nucleic-acids were not detected.



sample type △ liquid ○ solids
Fig 2. Comparison of HIV nucleic acid quantification in liquids and solids. Concentrations of HIV nucleic acids in wastewater liquids (black triangles) and solids (blue circles) from OSP and SEP expressed in terms of copies of the target per mL liquid wastewater or grams dry weight of solids found in wastewater. Open circles or triangles show where HIV nucleic acids were not detected.



414

415 Fig 3. Comparison of HIV nucleic acid quantification with and without RT. Concentrations

416 of HIV nucleic acids in wastewater solids from OSP and SEP are expressed in terms of copies

417 of the target per gram dry weight of solids found in wastewater for quantification with the use of

418 RT (blue) and without (black). Errors on each bar represent standard deviations (68%

- 419 confidence intervals) from the droplet digital RT-PCR measurement and include Poisson error
- 420 as well as variation among replicate wells.

400		
422		
423		
424	Refe	erences
425		
426	(1)	Why the HIV epidemic is not over. https://www.who.int/news-room/spotlight/why-the-hiv-
427	( )	epidemic-is-not-over (accessed 2024-01-29).
428	(2)	HIV Surveillance   Reports  Resource Library   HIV/AIDS   CDC.
429	( )	https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (accessed 2024-03-08).
430	(3)	HIV Surveillance   Reports  Resource Library   HIV/AIDS   CDC.
431	( )	https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html (accessed 2024-03-08).
432	(4)	CDC-Funded HIV Testing in the United States, Puerto Rico, and the U.S. Virgin Islands,
433	. ,	2020.; Centers for Disease Control and Prevention, 2022.
434		https://www.cdc.gov/hiv/library/reports/index.html (accessed 2024-03-10).
435	(5)	CDC-Funded HIV Testing in the United States, Puerto Rico, and the U.S. Virgin Islands,
436		2021.; Centers for Disease Control and Prevention, 2023.
437		https://www.cdc.gov/hiv/library/reports/index.html (accessed 2024-03-10).
438	(6)	Estimated HIV Incidence and Prevalence in the United States, 2017–2021. HIV
439		Surveillance Supplemental Report, 2023; 28 (No.3); Centers for Disease Control and
440		Prevention, 2023. https://www.cdc.gov/hiv/library/reports/index.html (accessed 2024-03-
441		10).
442	(7)	Hoover, K. W. HIV Services and Outcomes During the COVID-19 Pandemic — United
443		States, 2019–2021. MMWR Morb. Mortal. Wkly. Rep. 2022, 71.
444		https://doi.org/10.15585/mmwr.mm7148a1.
445	(8)	Boehm, A. B.; Hughes, B.; Duong, D.; Chan-Herur, V.; Buchman, A.; Wolfe, M. K.; White,
446		B. J. Wastewater Concentrations of Human Influenza, Metapneumovirus, Parainfluenza,
447		Respiratory Syncytial Virus, Rhinovirus, and Seasonal Coronavirus Nucleic-Acids during
448		the COVID-19 Pandemic: A Surveillance Study. Lancet Microbe 2023, 4 (5).
449	$\langle 0 \rangle$	Rttps://doi.org/10.1016/S2666-5247(22)00386-X.
450	(9)	Peccia, J.; Zuill, A.; Brackney, D. E.; Grubaugh, N. D.; Kapian, E. H.; Casanovas-Massana,
401		A., KO, A. I., Malik, A. A., Waliy, D., Waliy, M., Waltell, J. L., Weiliberger, D. M., Offer, S.
452		b. SARS-COV-2 RNA Concentrations in Finnary Municipal Sewaye Sludge as a Leading
455		https://doi.org/10.1101/2020.05.10.20105000
454	(10)	$M_{O}$ Molfe M K · Vu A T · Duong D · Rane M S · Hughes B · Chan-Herur V · Donnelly M ·
456	(10)	Chai S: White B. L: Vugia D. L: Roehm A. B. Use of Wastewater for Moox Outbreak
457		Surveillance in California N Engl J Med <b>2023</b> 388 (6) 570–572
458		https://doi.org/10.1056/NF.IMc2213882
459	(11)	Boehm, A. B.; Wolfe, M. K.; White, B. J.; Hughes, B.; Duong, D.; Banaei, N.; Bidwell, A.
460	()	Human Norovirus (HuNoV) GII RNA in Wastewater Solids at 145 United States
461		Wastewater Treatment Plants: Comparison to Positivity Rates of Clinical Specimens and
462		Modeled Estimates of HuNoV GII Shedders. J. Expo. Sci. Environ. Epidemiol. 2023, 1–8.
463		https://doi.org/10.1038/s41370-023-00592-4.
464	(12)	Boehm, A. B.; Hughes, B.; Duong, D.; Banaei, N.; White, B. J.; Wolfe, M. K. A
465	( )	Retrospective Longitudinal Study of Adenovirus Group F, Norovirus GI and GII, Rotavirus,
466		and Enterovirus Nucleic-Acids in Wastewater Solids at Two Wastewater Treatment Plants:
467		Solid-Liquid Partitioning and Relation to Clinical Testing Data. medRxiv August 31, 2023, p
468		2023.08.29.23294748. https://doi.org/10.1101/2023.08.29.23294748.
469	(13)	Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Vugia, D. J.; Yu, A. T.; Li, L.;
470		Balliet, M.; Stoddard, P.; Han, G. S.; Wigginton, K. R.; Boehm, A. B. High-Frequency,
471		High-Throughput Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight

- 472 Publicly Owned Treatment Works in Northern California Shows Strong Association with
- 473 COVID-19 Incidence. *mSystems* 6 (5), e00829-21.
- 474 https://doi.org/10.1128/mSystems.00829-21.
- 475 (14) Wolfe, M. K.; Duong, D.; Bakker, K. M.; Ammerman, M.; Mortenson, L.; Hughes, B.; Arts, 476 P.; Lauring, A. S.; Fitzsimmons, W. J.; Bendall, E.; Hwang, C. E.; Martin, E. T.; White, B. 477 J.; Boehm, A. B.; Wigginton, K. R. Wastewater-Based Detection of Two Influenza 478 Outbreaks. Environ. Sci. Technol. Lett. 2022, 9 (8), 687-692.
- 479 https://doi.org/10.1021/acs.estlett.2c00350.
- (15) Preston, D. R.; Farrah, S. R.; Bitton, G.; Chaudhry, G. R. Detection of Nucleic Acids 480 481 Homologous to Human Immunodeficiency Virus in Wastewater. J. Virol. Methods 1991, 33 482 (3), 383–390. https://doi.org/10.1016/0166-0934(91)90038-2.
- 483 (16) Ansari, S. A.; Farrah, S. R.; Chaudhry, G. R. Presence of Human Immunodeficiency Virus 484 Nucleic Acids in Wastewater and Their Detection by Polymerase Chain Reaction. Appl. 485 Environ. Microbiol. 1992, 58 (12), 3984–3990.
- 486 (17) Casson, L. W.; Ritter, M. O. D.; Cossentino, L. M.; Gupta, P. Survival and Recovery of 487 Seeded HIV in Water and Wastewater. Water Environ. Res. 1997, 69 (2), 174–179.
- 488 (18) Moore, B. E. Survival of Human Immunodeficiency Virus (HIV), HIV-Infected Lymphocytes, 489 and Poliovirus in Water. Appl. Environ. Microbiol. 1993, 59 (5), 1437-1443. 490 https://doi.org/10.1128/aem.59.5.1437-1443.1993.
- 491 (19) Chakrabarti, A. K.; Caruso, L.; Ding, M.; Shen, C.; Buchanan, W.; Gupta, P.; Rinaldo, C. 492 R.; Chen, Y. Detection of HIV-1 RNA/DNA and CD4 mRNA in Feces and Urine from 493 Chronic HIV-1 Infected Subjects with and without Anti-Retroviral Therapy. AIDS Res. Ther. 494 2009, 6, 20. https://doi.org/10.1186/1742-6405-6-20.
- 495 (20) van der Hoek, L.; Boom, R.; Goudsmit, J.; Snijders, F.; Sol, C. J. Isolation of Human 496 Immunodeficiency Virus Type 1 (HIV-1) RNA from Feces by a Simple Method and 497 Difference between HIV-1 Subpopulations in Feces and Serum. J. Clin. Microbiol. 1995, 33 498 (3), 581–588. https://doi.org/10.1128/jcm.33.3.581-588.1995.
- 499 (21) Zuckerman, R. A.; Whittington, W. L. H.; Celum, C. L.; Collis, T. K.; Lucchetti, A. J.; Sanchez, J. L.; Hughes, J. P.; Sanchez, J. L.; Coombs, R. W. Higher Concentration of HIV 500 501 RNA in Rectal Mucosa Secretions than in Blood and Seminal Plasma, among Men Who 502 Have Sex with Men, Independent of Antiretroviral Therapy. J. Infect. Dis. 2004, 190 (1), 503 156-161. https://doi.org/10.1086/421246.
- 504 (22) Wolfe, M. K.; Topol, A.; Knudson, A.; Simpson, A.; White, B.; Duc, V.; Yu, A.; Li, L.; Balliet, 505 M.; Stoddard, P.; Han, G.; Wigginton, K. R.; Boehm, A. High-Frequency, High-Throughput Quantification of SARS-CoV-2 RNA in Wastewater Settled Solids at Eight Publicly Owned 506 507 Treatment Works in Northern California Shows Strong Association with COVID-19 508 Incidence. mSystems 2021, 6 (5), e00829-21. https://doi.org/10.1128/mSystems.00829-21.
- 509 (23) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput Pre-Analytical 510 Processing of Wastewater Settled Solids for SARS-CoV-2 RNA Analyses. protocols.io 511
  - 2021. https://doi.org/dx.doi.org/10.17504/protocols.io.btyqnpvw.
- 512 (24) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong; 513 Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids Concentrations 514 in Wastewater Solids from Central and Coastal California USA. Sci. Data 2023, 10, 396.
- 515 (25) Topol, A.; Wolfe, M.; Wigginton, K.; White, B.; Boehm, A. High Throughput RNA Extraction 516 and PCR Inhibitor Removal of Settled Solids for Wastewater Surveillance of SARS-CoV-2 517 RNA. protocols.io 2021. https://doi.org/dx.doi.org/10.17504/protocols.io.btyrnpv6.
- 518 (26) Visseaux, B.; Damond, F.; Matheron, S.; Descamps, D.; Charpentier, C. Hiv-2 Molecular 519 Epidemiology. Infect. Genet. Evol. 2016, 46, 233–240.
- 520 https://doi.org/10.1016/j.meegid.2016.08.010.
- 521 (27) Kibirige, C. N.; Manak, M.; King, D.; Abel, B.; Hack, H.; Wooding, D.; Liu, Y.; Fernandez, 522 N.; Dalel, J.; Kave, S.; Imami, N.; Jagodzinski, L.; Gilmour, J. Development of a Sensitive,

- 523Quantitative Assay with Broad Subtype Specificity for Detection of Total HIV-1 Nucleic524Acids in Plasma and PBMC. Sci. Rep. 2022, 12 (1), 1550. https://doi.org/10.1038/s41598-525021-03016-1.
- 526 (28) Brussel, A.; Delelis, O.; Sonigo, P. Alu-LTR Real-Time Nested PCR Assay for Quantifying
  527 Integrated HIV-1 DNA. In *Human Retrovirus Protocols: Virology and Molecular Biology*;
  528 Zhu, T., Ed.; Methods in Molecular Biology<sup>™</sup>; Humana Press: Totowa, NJ, 2005; pp 139–
  529 154. https://doi.org/10.1385/1-59259-907-9:139.
- (29) Friedrich, B.; Li, G.; Dziuba, N.; Ferguson, M. R. Quantitative PCR Used to Assess HIV-1
  Integration and 2-LTR Circle Formation in Human Macrophages, Peripheral Blood
  Lymphocytes and a CD4+ Cell Line. *Virol. J.* 2010, 7 (1), 354.
- 533 https://doi.org/10.1186/1743-422X-7-354.
- 534 (30) McClary-Gutierrez, J. S.; Aanderud, Z. T.; Al-faliti, M.; Duvallet, C.; Gonzalez, R.; Guzman, 535 J.; Holm, R. H.; Jahne, M. A.; Kantor, R. S.; Katsivelis, P.; Kuhn, K. G.; Langan, L. M.; 536 Mansfeldt, C.; McLellan, S. L.; Mendoza Grijalva, L. M.; Murnane, K. S.; Naughton, C. C.; 537 Packman, A. I.; Paraskevopoulos, S.; Radniecki, T. S.; Roman, F. A.; Shrestha, A.; 538 Stadler, L. B.; Steele, J. A.; Swalla, B. M.; Vikesland, P.; Wartell, B.; Wilusz, C. J.; Wong, 539 J. C. C.; Boehm, A. B.; Halden, R. U.; Bibby, K.; Delgado Vela, J. Standardizing Data 540 Reporting in the Research Community to Enhance the Utility of Open Data for SARS-CoV-541 2 Wastewater Surveillance. Environ. Sci. Water Res. Technol. 2021, 7 (9), 1545–1551. 542 https://doi.org/10.1039/D1EW00235J.
- (31) Kantor, R. S.; Nelson, K. L.; Greenwald, H. D.; Kennedy, L. C. Challenges in Measuring
  the Recovery of SARS-CoV-2 from Wastewater. *Environ. Sci. Technol.* 2021, 55 (6),
  3514–3519. https://doi.org/10.1021/acs.est.0c08210.
- (32) Boehm, A. B.; Wolfe, M. K.; White, B. J.; Hughes, B.; Duong, D.; Bidwell, A. More than a
  Tripledemic: Influenza A Virus, Respiratory Syncytial Virus, SARS-CoV-2, and Human
  Metapneumovirus in Wastewater during Winter 2022–2023. *Environ. Sci. Technol. Lett.*2023, *10* (8), 622–627. https://doi.org/10.1021/acs.estlett.3c00385.
- (33) Boehm, A. B.; Wolfe, M. K.; White, B. J.; Hughes, B.; Duong, D. Two Years of Longitudinal Measurements of Human Adenovirus Group F, Norovirus GI and GII, Rotavirus, Enterovirus, Enterovirus D68, Hepatitis A Virus, Candida Auris, and West Nile Virus Nucleic-Acids in Wastewater Solids: A Retrospective Study at Two Wast.... medRxiv 2023. https://doi.org/10.1101/2023.08.22.23294424.
- (34) Topol, A.; Wolfe, M.; White, B.; Wigginton, K.; Boehm, A. High Throughput SARS-COV-2,
   PMMOV, and BCoV Quantification in Settled Solids Using Digital RT-PCR. *protocols.io* 2021. https://doi.org/dx.doi.org/10.17504/protocols.io.btywnpxe.
- (35) Sexually Transmitted Infections (STI) and HIV Epidemiology Annual Report, 2022; County
   of Santa Clara Public Health Department Infectious Disease and Response Branch, 2023.
   https://publichealth.sccgov.org/sites/g/files/exjcpb916/files/documents/STIHIV\_AnnualRep
   ort\_2022.pdf (accessed 2024-03-10).
- 562 (36) Sexually Transmitted Infections (STI) and HIV Epidemiology Annual Report, 2021; County
   563 of Santa Clara Public Health Department Infectious Disease and Response Branch, 2023.
   564 https://publichealth.sccgov.org/sites/g/files/exjcpb916/files/documents/STIHIV\_AnnualRep
   565 ort\_2021.pdf (accessed 2024-03-10).
- (37) *HIV Epidemiology Annual Report 2022*; San Francisco Department of Public Health
  Population Health Division HIV Epidemiology Section, 2023.
  https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2022-Orange.pdf
  (accessed 2024-03-10).
- 570 (38) E-2. California County Population Estimates and Components of Change by Year July
  571 1, 2020-2023 | Department of Finance; 2023.
- 572 https://dof.ca.gov/forecasting/demographics/estimates/e-2/ (accessed 2024-03-11).
- 573 (39) Boehm, A. B.; Hughes, B.; Duong, D.; Banaei, N.; White, B. J.; Wolfe, M. K. A

- 574Retrospective Longitudinal Study of Adenovirus Group F, Norovirus GI and GII, Rotavirus,575and Enterovirus Nucleic-Acids in Wastewater Solids at Two Wastewater Treatment Plants:
- 576 Solid-Liquid Partitioning and Relation to Clinical Testing Data. *Revis. MSphere* 2024.
  577 (40) *HIV Epidemiology Annual Report 2021*; San Francisco Department of Public Health
- 578 Population Health Division HIV Epidemiology Section, 2022.
  579 https://www.sfdph.org/dph/files/reports/RptsHIVAIDS/AnnualReport2021-Red.pdf
  580 (accessed 2024-03-10).
- (41) Branson, B. M.; Handsfield, H. H.; Lampe, M. A.; Janssen, R. S.; Taylor, A. W.; Lyss, S. B.;
  Clark, J. E.; Centers for Disease Control and Prevention (CDC). Revised
  Recommendations for HIV Testing of Adults, Adolescents, and Pregnant Women in
  Health-Care Settings. *MMWR Recomm. Rep. Morb. Mortal. Wkly. Rep. Recomm. Rep.*2006, 55 (RR-14), 1–17; guiz CE1-4.
- 586 (42) Olatosi, B.; Siddiqi, K. A.; Conserve, D. F. Towards Ending the Human Immunodeficiency
  587 Virus Epidemic in the US. *Medicine (Baltimore)* 2020, 99 (2), e18525.
  588 https://doi.org/10.1097/MD.00000000018525.
- (43) Berg, L. J.; Delgado, M. K.; Ginde, A. A.; Montoy, J. C.; Bendavid, E.; Camargo, C. A.
  Characteristics of U.S. Emergency Departments That Offer Routine Human
  Immunodeficiency Virus Screening. *Acad. Emerg. Med. Off. J. Soc. Acad. Emerg. Med.*2012, 19 (8), 894–900. https://doi.org/10.1111/j.1553-2712.2012.01401.x.
- 593 (44) Shirreffs, A.; Lee, D. P.; Henry, J.; Golden, M. R.; Stekler, J. D. Understanding Barriers to
  594 Routine HIV Screening: Knowledge, Attitudes, and Practices of Healthcare Providers in
  595 King County, Washington. *PLOS ONE* **2012**, 7 (9), e44417.
  596 https://doi.org/10.1371/journal.pone.0044417.
- 597
- 598
- 599
- 600